Analysis of the clinical effect of fluorescein sodium assisted resection and prognosis of high grade gliomas

doi:10.3877/cma.j.issn.2095-123X.2020.03.003

Abstract

Abstract:

Objective

To evaluate the clinical effect of fluorescein sodium assisted microsurgery for high-grade gliomas.

Methods

From January 2015 to January 2018, 85 patients with high-grade gliomas confirmed by Neurosurgery Department of the First Affiliated Hospital of Xiamen University were retrospectively enrolled. According to whether fluorescein sodium was used in tumor resection, they were divided into fluorescein sodium operation group (52 cases) and conventional operation group (33 cases). The general clinical data [gender, age, side, maximum diameter of tumor, cystic and solid condition, preoperative Karnofsky performance status (KPS) score], KPS score was poor before and after operation, operation time, blood loss, postoperative complications, total tumor resection, progression free survival (PFS) and overall survival time (OS) were compared between the two groups.

Results

There was no significant difference in general clinical data between the two groups (P>0.05). There was no significant difference in KPS score was poor before and after operation and intraoperative blood loss between the two groups (P>0.05). There were significant differences in operation time, postoperative complications, total tumor resection rate, PFS and OS between the two groups (P<0.05).

Conclusion

fluorescein sodium assisted microsurgery for high-grade gliomas can significantly improve the total tumor resection rate, shorten the operation time, prolong the PFS and OS time, and benefit the patients with high-grade glioma.

Key words: High grade glioma, Fluorescein sodium, Gross-total resection, Overall survival

Yukui Li, Weichao Jiang, Sifang Chen, Xi Chen, Zhi Zhu, Xiaoman Zhou, Guowei Tan. Analysis of the clinical effect of fluorescein sodium assisted resection and prognosis of high grade gliomas[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2020, 10(03): 139-143.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2020.03.003

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2020/V10/I03/139

Figures/Tables 5

References 20

[1]	Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review[J]. Neuro Oncol, 2014, 16(7): 896-913.
[2]	Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.
[3]	国家卫生健康委员会医政医管局.脑胶质瘤诊疗规范(2018年版)[J].中华神经外科杂志, 2019, 35(3): 217-239.
[4]	Ostrom QT, Gittleman H, Stetson L, et al. Epidemiology of gliomas[J]. Cancer Treat Res, 2015, 163: 1-14.
[5]	Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996.
[6]	房莉,章诗伟,李晶,等.脑胶质瘤患者预后影响因素分析[J].中国肿瘤, 2014, 23(12): 1019-1023.
[7]	李德培,陈银生,郭琤琤,等.脑胶质瘤的临床疗效和预后因素分析(附741例报告)[J].中华神经外科杂志, 2018, 34(9): 905-909.
[8]	Acerbi F, Cavallo C, Broggi M, et al. Fluorescein-guided surgery for malignant gliomas: a review[J]. Neurosurg Rev, 2014, 37(4): 547-557.
[9]	中华医学会放射肿瘤治疗学分会.胶质瘤放疗中国专家共识(2017)[J].中华放射肿瘤学杂志, 2018, 27(2): 123-131.
[10]	Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: response assessment in neuro-oncology (RANO) working group[J]. Neurosurgery, 2012, 70(1): 234-243; discussion 243-244.
[11]	Stoyanov GS, Dzhenkov DL. On the concepts and history of glioblastoma multiforme-morphology, genetics and epigenetics[J]. Folia Med (Plovdiv), 2018, 60(1): 48-66.
[12]	中国脑胶质瘤协作组,中国脑胶质瘤基因组图谱计划.中国脑胶质瘤分子诊疗指南[J].中华神经外科杂志, 2014, 30(5): 435-444.
[13]	Dilek O, Ihsan A, Tulay H. Anaphylactic reaction after fluorescein sodium administration during intracranial surgery[J]. J Clin Neurosci, 2011, 18(3): 430-431.
[14]	胡晨阳,李旭琴.荧光素钠引导下胶质瘤切除的临床应用及研究进展[J].中国微侵袭神经外科杂志, 2019, 24(3): 142-144.
[15]	张义松,苏宁.荧光引导下恶性胶质瘤切除的临床研究进展[J].中国微侵袭神经外科杂志, 2017, 22(6): 284-286.
[16]	Catapano G, Sgulò FG, Seneca V, et al. Fluorescein-guided surgery for high-grade glioma resection: an intraoperative "contrast-enhancer" [J]. World Neurosurg, 2017, 104: 239-247.
[17]	何桂录,马宇强,陈保东.荧光素钠在脑胶质瘤术中的应用进展[J].中华神经外科杂志, 2019, 35(5): 537-540.
[18]	王忠,张瑞剑,韩志桐,等.多模态功能神经导航联合术中荧光素钠辅助成像技术在颅内恶性肿瘤手术中的应用[J].中国综合临床, 2020, 36(2): 97-101.
[19]	Su X, Huang QF, Chen HL, et al. Fluorescence-guided resection of high-grade gliomas: a systematic review and meta-analysis[J]. Photodiagnosis Photodyn Ther, 2014, 11(4): 451-458.
[20]	Katsevman GA, Turner RC, Urhie O, et al. Utility of sodium fluorescein for achieving resection targets in glioblastoma: increased gross- or near-total resections and prolonged survival[J]. J Neurosurg, 2019: 1-7.

项目		荧光素钠手术组（n=52）	常规手术组（n=33）	χ²/t值	P值
性别[例（%）]				1.797	0.180
	男	27（51.9）	22（66.7）
	女	25（48.1）	11（33.3）
年龄（岁，Mean±SD）		52.0±14.3	52.1±14.0	-0.019	0.985
肿瘤最大直径（cm，Mean±SD）		4.9±1.4	4.7±1.5	0.751	0.455
肿瘤所在侧别[例（%）]				1.968	0.161
	左侧	27（51.9）	12（36.4）
	右侧	25（48.1）	21（63.6）
肿瘤囊实性[例（%）]				0.694	0.405
	实性	17	8
	囊实性	35	25
术前KPS评分		81.5±23.0	76.0±26.5	1.002	0.319
手术时长（min，Mean±SD）		353.7±89.3	415.2±124.6	-2.647	0.010
术中出血量（mL，Mean±SD）		439.4±348.3	451.5±262.3	-0.171	0.865
手术前后KPS评分差（分，Mean±SD）		-1.73±16.1	-2.73±19.7	0.255	0.799
术后并发症[例（%）]				4.638	0.031
	发生	49（94.2）	26（78.8）
	未发生	3（5.8）	7（21.2）
肿瘤切除情况[例（%）]				8.091	0.004
	全切除	50（96.2）	25（75.8）
	非全切除	2（3.8）	8（24.2）

项目		荧光素钠手术组（n=52）	常规手术组（n=33）	χ²/t值	P值
性别[例（%）]				1.797	0.180
	男	27（51.9）	22（66.7）
	女	25（48.1）	11（33.3）
年龄（岁，Mean±SD）		52.0±14.3	52.1±14.0	-0.019	0.985
肿瘤最大直径（cm，Mean±SD）		4.9±1.4	4.7±1.5	0.751	0.455
肿瘤所在侧别[例（%）]				1.968	0.161
	左侧	27（51.9）	12（36.4）
	右侧	25（48.1）	21（63.6）
肿瘤囊实性[例（%）]				0.694	0.405
	实性	17	8
	囊实性	35	25
术前KPS评分		81.5±23.0	76.0±26.5	1.002	0.319
手术时长（min，Mean±SD）		353.7±89.3	415.2±124.6	-2.647	0.010
术中出血量（mL，Mean±SD）		439.4±348.3	451.5±262.3	-0.171	0.865
手术前后KPS评分差（分，Mean±SD）		-1.73±16.1	-2.73±19.7	0.255	0.799
术后并发症[例（%）]				4.638	0.031
	发生	49（94.2）	26（78.8）
	未发生	3（5.8）	7（21.2）
肿瘤切除情况[例（%）]				8.091	0.004
	全切除	50（96.2）	25（75.8）
	非全切除	2（3.8）	8（24.2）

Please choose a citation manager

Content to export